Agenus Advances Portfolio with 6 Clinical Collaborations
LEXINGTON, Mass., May 31, 2022 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company…
LEXINGTON, Mass., May 31, 2022 (GLOBE NEWSWIRE) — Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company…
Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor in clinical development at Fortress’ subsidiary…
SciSparc will use its SCI-160 technology platform for treating pain in combination with Polyrizons‘ Trap…
CINCINNATI, May 31, 2022 (GLOBE NEWSWIRE) — Blue Water Vaccines Inc. (“BWV” or “Blue Water…
ISELIN, N.J., May 31, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial…
TEL AVIV, Israel and NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq:…
THE WOODLANDS, Texas, May 31, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today…
– Company preparing to dose first patients in pivotal Phase 3 ASCEND clinical trial –…
ZUG, Switzerland and CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP),…
— Overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had…
LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) — Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical…
BIIB122 is an inhibitor of LRRK2, a potential novel target intended to impact the underlying…
Promising preliminary clinical results validate expansion of study initially into the United Kingdom FLORHAM PARK,…
Updated data from Phase 1/2a study show median duration of response greater than 21 months…
LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) — (NASDAQ: ENOB) – Enochian BioSciences is working…
Ovarian Cancer ID8 Study – Survival Probability Source image Stand-alone therapy with PD1 checkpoint inhibitors…
MONTREAL, May 31, 2022 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH)…
GAITHERSBURG, Md., May 31, 2022 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical…
New PDUFA goal date of December 28, 2022 NEW YORK, May 31, 2022 (GLOBE NEWSWIRE)…
On the strength of its unique Voice Marketing Platform, Instreamatic is honored for exceptional innovation…